ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial

• Status: Completed
• Trial end date: 2003-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE (up to 60 % without prophylaxis). The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but heparins have to be applied below the skin (subcutaneously). Additionally, there is a chance of developing a heparin-induced thrombocytopenia (decrease in platelets). Therefore, there is still a need for new agents which are safer and more efficient and which are easier to apply.The purpose of this study is to compare the safety and efficacy of BAY 59-7939 with the safety and efficacy of the licensed drug Enoxaparin. Enoxaparin, a so-called low molecular heparin, is approved and widely used in the area of thromboprophylaxis and will be given once daily subcutaneously.Another important purpose of the study is to find the optimal dose of BAY 59-7939 for thromboprophylaxis after hip replacement surgery. Therefore, there are several dose steps planned.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Enoxaparin; Rivaroxaban

Criteria

Inclusion Criteria:

• Male patients aged 18 years or above and postmenopausal female patients.

• Patients scheduled for elective primary total hip replacement (cemented or non-cemented prosthesis).

• Patients' written informed consent for participation after receiving detailed written and oral previous information to any study specific procedures.

Exclusion Criteria:

• DVT or PE within the previous 6 months prior to study entry.

• Myocardial infarction (MI) or cerebrovascular attack (CVA), TIA or ischaemic stroke within the last 6 months prior to study entry.

• History of heparin-induced thrombocytopenia, allergy to heparins.

• Intracerebral or intraocular bleeding within the last 6 months prior to study entry.

• History of gastrointestinal disease with gastrointestinal bleeding within the last 6 months prior to the study.

• History or presence of gastrointestinal disease which could result in an impaired absorption of the study drug

• Amputation of one leg.Related to current symptoms or findings

• Heart insufficiency NYHA III-IV.

• Congenital or acquired haemorrhagic diathesis (PT INR/aPTT not within normal limits).

• Thrombocytopenia (platelets < 50.000/µl).

• Macroscopic haematuria.

• Allergy to contrast media.

• Severe hypertension (SBP > 200mmHg, DBP > 100 mmHg).

• Impaired liver function (transaminases > 2 x ULN).

• Impaired renal function (serum creatinine > 1.5 x ULN).

• Active malignant disease.

• Presence of active peptic ulcer or gastrointestinal disease with increased risk of gastrointestinal bleeding.

• Body weight < 45 kg.

• Drug- or alcohol abuse.

• Related to current treatment

• Therapy with oral anticoagulants (e.g. phenprocoumon, warfarin-sodium).

• Therapy with acetylic salicylic acid or other thrombocyte aggregation inhibitors (e.g. clopidogrel, dipyridamole and ticlopidine) should be stopped one week before enrolment

• Treatment with heparins or Factor Xa Inhibitors other than study medication.

• All other drugs influencing coagulation, (exception: NSAIDs with half life < 17 hrs will be allowed).